Pushing the boundaries of imaging technology

We’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

Clinical trial imaging

Harnessing the power of Imaging Phenomics

We’re transforming the science of medical imaging. By harnessing the power of Imaging Phenomics we can improve current treatment, enhance diagnosis and accelerate development of next generation therapies, helping make a healthier world for millions.

iBiopsy

We deliver on a global scale

The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.

Investors

Fredrik Brag at 3 Min Eco

Watch the latest interview with Fredrik Brag, Median’s CEO, for Boursorama 3 Min Eco show. This interview provides an update on the company’s outlook for 2020. It is in French but it has subtitles in English, so no reason to miss it!


Watch

Latest press releases

20 October 2020

Median Technologies records its eighth consecutive quarter of revenue growth

• Revenues totalling €9.4m over the first three quarters 2020, higher than 2019 yearly revenue (€9m)
• Q3 revenue of €3.5m, a 50% increase compared to Q3, 2019
• Order backlog of €50.7m
• Cash and cash equivalents of €17.3m

14 October 2020

Median Technologies announces its H1 2020 results

Strong revenue growth, accelerated investments and initial promising results for iBiopsy. Revenue surges 47.9% compared with the first half of 2019 at €5.9m. Order backlog up 40% over six months to €53.6m. Cash and cash equivalents of €19.4m as of June 30, 2020

8 September 2020

Promising results on the use of the iBiopsy® platform in the context of measuring the anti-tumor immune response

Median Technologies today announced the promising results of a first retrospective study on the implementation of the iBiopsy® platform for the analysis of patients with solid tumor cancer who are likely to be responsive to immuno-oncology treatments such as those based on immune checkpoint inhibitors (ICIs)

8 July 2020

Median Technologies:  Strong business activity for the first half of 2020 (unaudited figures)

First-half revenue up 47.9% to €5.9 million, compared with €4.0 million in H1 2019 – 7 consecutive quarters of revenue growth – Order backlog to €53.6 million as of June 30th, 2020, up 40% compared with order backlog as of December 31st, 2019 and up 74.6% compared with order backlog as of June 30th, 2019 – Cash and cash equivalents expected to reach €19.4 million

6 July 2020

Median Technologies is awarded the Euronext European Rising Tech Label

Median Technologies announced today that it has been awarded the Euronext European Rising Tech Label. The European Rising Tech Label recognizes 98 top-performing companies among more than 350 small and mid-caps listed on Euronext markets in Amsterdam, Brussels, Dublin, Lisbon and Paris, in the Tech sector (i.e., Life Sciences, Clean Tech and Technology, Media & Telecom).

1/5

Company Update Webcast

We were very pleased to welcome a large number of participants during our webcast held on July 9th, 2020. Fredrik Brag, CEO and Co-founder of Median presented our company’s latest news and outlook and answered the numerous questions from the audience.  You didn’t have the opportunity to join? here is the replay! (in French)

Webinars

DECEMBER 3rd, 2020 03:30PM CET

Regulatory Considerations on Imaging Endpoint Procedures in Oncology Trials: a Comparison of China NMPA and FDA Guidelines

In April 2020, The China National Medical Products Administration (NMPA) regulatory agency publicly solicited opinions on the draft guidelines on “Standard and Technical Guidelines for Imaging Endpoint Procedures for Clinical Trials of Anti-tumor Drugs”.

Please join our upcoming webinar: Dr. Yan Liu, Median’s CMO and a member of the expert panel who developed the NMPA guidelines, as well as Mr. Faisel Jobrani, Head of Median QA will provide you with a clear vision based on concrete examples. The webinar will be held in English.

Imaging for clinical trials

Advancing treatments of the future

Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.

Read more

iBiopsy®

Powering the phenomics revolution

We’re changing the game, transforming the landscape. We’re capturing the power of big data, cloud computing and artificial intelligence to create a new world of possibilities for biopharma compannies and healthcare professionals alike. Our iBiopsy® platform opens up the field of phenomics, driving the science of precision and predictive medicine.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Quick Links

Stock Market Data

TICKER: ALMDT ISIN: FR0011049824
Get in touch

Together, let's build the future of medicine

Contact us Jobs at Median